𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Postoperative adjuvant chemotherapy for operable esophageal cancer: A pilot clinical study

✍ Scribed by Dr. Sanjay Sharma; Anil K. D'Cruz; Rajan Kannan; Jatendra J. Vyas

Publisher
John Wiley and Sons
Year
1992
Tongue
English
Weight
327 KB
Volume
50
Category
Article
ISSN
0022-4790

No coin nor oath required. For personal study only.

✦ Synopsis

Thirty-eight patients with node positive squamous cell carcinoma of the esophagus were entered into a pilot clinical study using postoperative adjuvant chemotherapy (cisplatinum 100 mg/m2 and methotrexate 150 mg/m2 X 4 cycles) with an intent of improving cure rates and overall survival. Patient compliance was excellent and toxicity minimal. At 24 months of follow-up 22 patients (58%) were disease free, while 14 patients (37%) have relapsed and 2 were lost to follow-up. A highly significant correlation was noted between the number of nodes involved, the grade of the tumour, and the response to chemotherapy. Patients with poorly differentiated tumours and those with more than 4 nodes involved were more likely to develop recurrent disease (P < 0.01 and P < 0.005). We conclude that postoperative chemotherapy following resection for carcinoma of the esophagus is well tolerated with minimal side effects. It may also have an impact on improving disease free and overall survival.

πŸ“œ SIMILAR VOLUMES

Significant clinical response of activat
Significant clinical response of activated carbon adsorbed-peplomycin against esophageal cancer: A pilot study
✍ Kazuya Kitamura; Akeo Hagiwara; Tsunetoshi Sasabe; Osamu Kojima; Toshio Takahash πŸ“‚ Article πŸ“… 1993 πŸ› John Wiley and Sons 🌐 English βš– 403 KB

## Abstract Activated carbon particle adsorbed‐peplomycin (PEP‐CH) was administered to three patients who had advanced esophageal cancer and its clinical usefulness was evaluated. The PEP‐CH was injected endoscopically into the tumor or the adjacent normal esophageal tissue. Case 1 and case 3 were

A randomized trial of adjuvant endocrine
A randomized trial of adjuvant endocrine therapy, chemotherapy, and chemoendocrine therapy for operable breast cancer stratified by estrogen receptors
✍ Yasuo Nomura; Hideya Tashiro; Kazufumi Hisamatsu; Katsuko Shinozuka πŸ“‚ Article πŸ“… 1988 πŸ› John Wiley and Sons 🌐 English βš– 660 KB

Based on estrogen receptor (ER) status and menopausal status, operable breast cancer (International Union Against Cancer [UICC] Stage I, II, and III) patients were randomized for adjuvant endocrine therapy, chemotherapy, and chemoendocrine therapy, and the effects on the disease-free survival (DFS)